AG-EE 623 ZW
Categoria
AG-EE 623 ZW Nombres de marca, AG-EE 623 ZW Analogos
AG-EE 623 ZW Marca los nombres de mezcla
AG-EE 623 ZW Formula quimica
C27H36N2O4
AG-EE 623 ZW RX enlace
http://www.rxlist.com/cgi/generic/prandin.htm
AG-EE 623 ZW FDA hoja
AG-EE 623 ZW MSDS (hoja de seguridad de materiales)
AG-EE 623 ZW Sintesis de referencia
W. Grell et al., Int. PCT. pat. Appl. WO 93 00337
AG-EE 623 ZW Peso molecular
452.586 g/mol
AG-EE 623 ZW Punto de fusion
130-131 oC
AG-EE 623 ZW H2O Solubilidad
No hay información disponible
AG-EE 623 ZW Estado
Solid
AG-EE 623 ZW LogP
5.798
AG-EE 623 ZW Formas de dosificacion
Tableta
AG-EE 623 ZW Indicacion
Para el tratamiento de la diabetes mellitus tipo II.
AG-EE 623 ZW Farmacologia
Repaglinida es un sangre por vía oral para disminuir la glucosa de drogas de la clase meglitinida utilizados en el tratamiento de diabetes mellitus tipo 2 (también conocida como diabetes no insulino dependiente mellitus o NIDDM). Repaglinida disminuye los niveles de glucosa en la sangre, estimulando la secreción de insulina del páncreas. Esta acción depende de funcionamiento de las células beta de los islotes pancreáticos. La liberación de insulina es dependiente de la glucosa y disminuye en las concentraciones de glucosa baja.
AG-EE 623 ZW Absorcion
Rápido (la biodisponibilidad es del 56%)
AG-EE 623 ZW Toxicidad
LD50> 1 g / kg (rata) (W. Grell)
AG-EE 623 ZW Informacion de Pacientes
PATIENT INFORMATION
Patients should be informed of the potential risks and advantages of Repaglinide (PRANDIN) and of alternative modes of therapy. They should also be informed about the importance of adherence to dietary instructions, of a regular exercise program, and of regular testing of blood glucose and HbA1c. The risks of hypoglycemia, its symptoms and treatment, and conditions that predispose to its development and concomitant administration of other glucose-lowering drugs should be explained to patients and responsible family members. Primary and secondary failure should also be explained.
Patients should be instructed to take Repaglinide before meals (2, 3, or 4 times a day preprandially). Doses are usually taken within 15 minutes of the meal but time may vary from immediately preceding the meal to as long as 30 minutes before the meal. Patients who skip a meal (or add an extra meal) should be instructed to skip (or add) a dose for that meal.
Patients should be informed of the potential risks and advantages of Repaglinide (PRANDIN) and of alternative modes of therapy. They should also be informed about the importance of adherence to dietary instructions, of a regular exercise program, and of regular testing of blood glucose and HbA1c. The risks of hypoglycemia, its symptoms and treatment, and conditions that predispose to its development and concomitant administration of other glucose-lowering drugs should be explained to patients and responsible family members. Primary and secondary failure should also be explained.
Patients should be instructed to take Repaglinide before meals (2, 3, or 4 times a day preprandially). Doses are usually taken within 15 minutes of the meal but time may vary from immediately preceding the meal to as long as 30 minutes before the meal. Patients who skip a meal (or add an extra meal) should be instructed to skip (or add) a dose for that meal.
AG-EE 623 ZW Organismos afectados
Humanos y otros mamíferos
